[Efficiency and safety of different etoricoxib regimens in patients with axial spondyloarthritis, including ankylosing spondylitis].

Abstract

AIM:

To study the clinical and laboratory efficiency and safety of different etoricoxib (ET) regimens in patients with axial spondyloarthritis (axSpA), including ankylosing spondylitis.

SUBJECTS AND METHODS:

Forty patients with high axSpA activity (Bath Ankylosing Disease Activity Index (BASDAI 4) were examined and randomized to 2 groups: 1) 30 patients who received ET 90 mg continuously every day; 2) 10 patients who took the drug in the same dose intermittently 1-3 times weekly. The activity of axSpA (BASDAI, Ankylosing Spondylitis Disease Activity Score (ASDAS), erythrocyte sedimentation rate (ESR), and high-sensitivity C-reactive protein (hs-CRP)) was evaluated at baseline, 2 and 12 weeks; adverse events were recorded at baseline, 2, 6, and 12 weeks. The number of patients who had achieved an ASAS40 response at 2 and 12 weeks were taken into consideration. RESULTS At 12 weeks, the continuous administration group displayed decreases in BASDAI from 8 to 4, in ASDAS from 3.8 to 2.6, and in hs-CRP levels from 9.5 to 3.9 mg/l; the intermittent administration group exhibited decreases in BASDAI from 7.6 to 6.0, in ASDAS from 3.5 to 3.1, and hs-CRP from 8.8 to 4.5 mg/l (p<0.05). At this time, an AS40 response was achieved by 22 (73.3%) and 2 (20%) patients in Groups 1 and 2, respectively (p<0.05 for all). No serious adverse events were recorded.

CONCLUSION:

The efficacy of ET given in a daily dose of 90 mg was much higher than that of the drug used thrice or less weekly in the patients with axSpA.

• Authors: I Z Gaydukova, A P Rebrov
• Journal: Terapevticheskii arkhiv (Ter Arkh) Vol. 87 Issue 3 Pg. 77-82 ( 2015) ISSN: 0040-3660 [Print] Russia (Federation)
• PMID: 26027245 (Publication Type: Journal Article, Randomized Controlled Trial)

Chemical References

• Cyclooxygenase 2 Inhibitors
• Pyridines
• Sulfones
• Etoricoxib

Topics

• Adolescent
• Adult
• Cyclooxygenase 2 Inhibitors (administration & dosage, adverse effects, therapeutic use)
• Dose-Response Relationship, Drug
• Drug Administration Schedule
• Etoricoxib
• Female
• Humans
• Male
• Middle Aged
• Pyridines (administration & dosage, adverse effects, therapeutic use)
• Spondylarthritis (drug therapy)
• Spondylitis, Ankylosing (drug therapy)
• Sulfones (administration & dosage, adverse effects, therapeutic use)
• Treatment Outcome
• Young Adult